Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
This study has been completed.
Study NCT00136409 Information provided by Dana-Farber Cancer Institute
First Received: August 25, 2005 Last Updated: June 2, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelofibrosis
Myeloid Metaplasia
Agnogenic Myeloid Metaplasia
Chronic Myelomonocytic Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Metaplasia
Myeloproliferative Disorders
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Leukemia, Myeloid
Lymphatic Diseases
Myelodysplastic-Myeloproliferative Diseases
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Splenic Diseases
Interventions listed in this trial
Imatinib mesylate
Additional drug interventions recognized in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Novartis
Back to top of Main Content
